Home Antibody All anti-CDKN2A antibodies
Anti-CDKN2A TRUEMAB Antibody Clone 8A1
TrueMAB Antibodies - Made against Authentic Protein Antigens
Also for CDKN2A (NM_000077)
|Full length human recombinant protein of human CDKN2A (NP_000068) produced in E.coli.|
|| WB 1:2000,
|PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.|
|Purified from mouse ascites fluids by affinity chromatography
|Homo sapiens cyclin-dependent kinase inhibitor 2A (CDKN2A), transcript variant 1|
|ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4;|
Entrez Gene 1029 Human
|This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]. |
|Druggable Genome Cell cyclep53 signaling pathwayPathways in cancerPancreatic cancerGliomaMelanomaMore Pathways >> |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDKN2A (RC220937, Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-CDKN2A.